Table 3.
Subgroup analysis of H. pylori infection and the risk of TN types.
| Subgroups | Samples | H. pylori | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|---|---|
| n (%) | TN types | Controls | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Gender | ||||||
| Male | 25,307 (58.3%) | 6,409 (49.2%) | 18,898 (62.2%) | 1.04 (0.98–1.10) | 1.01 (0.95–1.08) | 1.01 (0.95–1.07) |
| Female | 18,096 (41.7%) | 6,625 (50.8%) | 11,471 (37.8%) | 1.12 (1.05–1.20)* | 1.02 (0.96–1.10) | 1.02 (0.95–1.09) |
| Age | ||||||
| <30 | 5,753 (13.3%) | 635 (4.9%) | 5,118 (16.8%) | 1.13 (0.95–1.34) | 1.16 (0.97–1.39) | 1.19 (0.99–1.43) |
| 30–39 | 10,708 (24.7%) | 1,746 (13.4%) | 8,962 (29.5%) | 1.09 (0.98–1.21) | 1.10 (0.99–1.23) | 1.11 (0.99–1.24) |
| 40–49 | 10,475 (24.1%) | 3,070 (23.6%) | 7,405 (24.4%) | 1.05 (0.96–1.14) | 1.06 (0.97–1.16) | 1.04 (0.95–1.15) |
| 50–59 | 9,464 (21.8%) | 3,746 (28.7%) | 5,718 (18.8%) | 0.91 (0.94–0.99)* | 0.92 (0.85–1.01) | 0.92 (0.84–1.00) |
| ≥60 | 7,010 (16.1%) | 3,839 (29.4%) | 3,171 (10.4%) | 0.98 (0.89–1.08) | 0.96 (0.87–1.06) | 0.96 (0.87–1.06) |
| BMI | ||||||
| <18.5 | 1,710 (4.2%) | 372 (3.1%) | 1,338 (4.7%) | 1.10 (0.87–1.39) | 1.03 (0.80–1.33) | 0.99 (0.76–1.29) |
| 18.5–23 | 16,370 (40.2%) | 4,593 (37.7%) | 11,777 (41.3%) | 1.13 (1.05–1.21)* | 1.06 (0.98–1.14) | 1.06 (0.98–1.14) |
| 23–27.5 | 18,059 (44.4%) | 5,753 (47.2%) | 12,306 (43.2%) | 1.02 (0.96–1.09) | 0.98 (0.92–1.05) | 0.97 (0.90–1.04) |
| ≥27.5 | 4,557 (11.2%) | 1,464 (12.0%) | 3,093 (10.8%) | 1.06 (0.94–1.20) | 1.03 (0.90–1.18) | 1.05 (0.92–1.21) |
Model 1: unadjusted; Model 2: adjusted for gender, age, BMI, SP, and DP; Model 3: Model 2 + adjusted for TCH, TG, LDL, and HDL.
TN, thyroid nodule; CI, confidence interval; BMI, body mass index; SP, systolic pressure; DP, diastolic pressure; TCH, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
*P value is considered statistically significant.